FRIDAY, Nov. 1, 2024 (HealthDay News) — The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide — the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy — had a nearly 14%Continue Reading
FRIDAY, Nov. 1, 2024 (HealthDay News) — Hillary Fisher thinks receiving weight-loss surgery as a teenager put her on the path to a better life. Fisher is one of 260 teens who participated in a long-term study which recently concluded that weight-loss surgery can bring lasting health benefits for obeseContinue Reading
WEDNESDAY, Oct. 30, 2024 (HealthDay News) — Pancreatic cancer rates are rising in adults younger than 50, but many continue to believe it’s a disease that only affects the elderly, a new survey shows. Folks in that age range also say they wouldn’t be able to identify early signs andContinue Reading
MONDAY, Oct. 28, 2024 (HealthDay News) — The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide — the active agent in Ozempic and Wegovy — had as much as a 52% reduction in kidney damage, as measured by urine testing,Continue Reading
FRIDAY, Oct. 25, 2024 (HealthDay News) — As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023,Continue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking sevenContinue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study claims. Obesity and all its attendant ills — type 2 diabetes, heart disease and cancer amongContinue Reading
-690x550.jpg)
THURSDAY, Oct. 17, 2024 (HealthDay News) — Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1), have a 50% lower rate of drunkenness thanContinue Reading
WEDNESDAY, Oct. 16, 2024 (HealthDay News) — Obesity is a more powerful driver of breast cancer than previously thought, a new study suggests. About 40% of hormone-positive breast cancers in postmenopausal women might be linked to excess body fat, researchers reported Oct. 15 in the Journal of Epidemiology & CommunityContinue Reading
TUESDAY, Oct. 15, 2024 (HealthDay News) — Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list. What prompted the FDA to reconsider its decision? On Oct.Continue Reading